Rohan Diwanji

636 total citations
8 papers, 206 citations indexed

About

Rohan Diwanji is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Rohan Diwanji has authored 8 papers receiving a total of 206 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Rohan Diwanji's work include Cancer Immunotherapy and Biomarkers (3 papers), Immune cells in cancer (2 papers) and Immune Cell Function and Interaction (2 papers). Rohan Diwanji is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Immune cells in cancer (2 papers) and Immune Cell Function and Interaction (2 papers). Rohan Diwanji collaborates with scholars based in United States, France and Spain. Rohan Diwanji's co-authors include Michail V. Sitkovsky, Radhika Kini, Akiko Ohta, Akio Ohta, Meenakshi Subramanian, Bob D. Brown, Jessica J. Gierut, Bo Young Kim, Marc Abrams and Wei Zhou and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Frontiers in Immunology.

In The Last Decade

Rohan Diwanji

8 papers receiving 202 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rohan Diwanji United States 4 93 70 59 29 28 8 206
Sze‐Fai Yip China 9 117 1.3× 31 0.4× 17 0.3× 20 0.7× 25 0.9× 22 250
Guillaume Morcrette France 7 117 1.3× 51 0.7× 26 0.4× 61 2.1× 41 1.5× 13 343
Ryosuke Ogawa Japan 8 102 1.1× 63 0.9× 21 0.4× 11 0.4× 35 1.3× 37 276
Srinivas Aluri United States 8 142 1.5× 29 0.4× 25 0.4× 39 1.3× 79 2.8× 30 291
Yasuyuki Nagao Japan 11 86 0.9× 43 0.6× 32 0.5× 20 0.7× 9 0.3× 34 276
Jong‐Mi Lee South Korea 9 55 0.6× 77 1.1× 13 0.2× 38 1.3× 10 0.4× 30 246
Rosina Maria Critelli Italy 9 77 0.8× 40 0.6× 24 0.4× 46 1.6× 25 0.9× 25 319
Clarissa Kooi Netherlands 6 100 1.1× 27 0.4× 38 0.6× 27 0.9× 6 0.2× 7 254
Gerben van der Vries Netherlands 7 113 1.2× 33 0.5× 31 0.5× 32 1.1× 7 0.3× 7 219
Toshiaki Kamano Japan 13 195 2.1× 46 0.7× 98 1.7× 66 2.3× 8 0.3× 31 382

Countries citing papers authored by Rohan Diwanji

Since Specialization
Citations

This map shows the geographic impact of Rohan Diwanji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohan Diwanji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohan Diwanji more than expected).

Fields of papers citing papers by Rohan Diwanji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohan Diwanji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohan Diwanji. The network helps show where Rohan Diwanji may publish in the future.

Co-authorship network of co-authors of Rohan Diwanji

This figure shows the co-authorship network connecting the top 25 collaborators of Rohan Diwanji. A scholar is included among the top collaborators of Rohan Diwanji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohan Diwanji. Rohan Diwanji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Singh, Reshma, Rohan Diwanji, Pushpa Jayaraman, et al.. (2020). Abstract A76: Anti IL-1b as a cancer immunotherapy. Cancer Immunology Research. 8(4_Supplement). A76–A76. 1 indexed citations
2.
Jayaraman, Pushpa, Vanessa Rodrik-Outmezguine, John M. Millholland, et al.. (2020). Abstract 5640: Targeting tumor-promoting inflammation (TPI) via the IL-1βpathway for cancer immunotherapy. Cancer Research. 80(16_Supplement). 5640–5640. 3 indexed citations
3.
Gardet, Agnès, Alex Pellerin, Christie‐Ann McCarl, et al.. (2019). Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus. Frontiers in Immunology. 10. 275–275. 30 indexed citations
4.
Jayaraman, Pushpa, John M. Millholland, Neil A. O’Brien, et al.. (2019). Abstract C103: Targeting IL-1β pathway for cancer immunotherapy. Molecular Cancer Therapeutics. 18(12_Supplement). C103–C103. 3 indexed citations
5.
Gierut, Jessica J., Wei Zhou, Michael Dills, et al.. (2018). Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases. Molecular Therapy. 26(7). 1771–1782. 22 indexed citations
6.
Lai, Cheng-Jung, Jessica J. Gierut, Utsav Saxena, et al.. (2018). Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria. Molecular Therapy. 26(8). 1983–1995. 83 indexed citations
7.
Wortham, Kathleen, Bo Ying, Hailin Yang, et al.. (2013). Abstract B222: Dicer substrate siRNAs to MYC, B-catenin, and other target genes effectively induce in vivo target gene knockdown and tumor inhibition.. Molecular Cancer Therapeutics. 12(11_Supplement). B222–B222. 1 indexed citations
8.
Ohta, Akio, Rohan Diwanji, Radhika Kini, et al.. (2011). In vivo T Cell Activation in Lymphoid Tissues is Inhibited in the Oxygen-Poor Microenvironment. SHILAP Revista de lepidopterología. 2. 27–27. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026